Osäkerhet kring IVF-reform i USA – svenskt bolag backar

Vita huset backar från Donald Trumps vallöfte om att öka tillgången till fertilitetsbehandlingar. Svenskt medicinteknikbolaget faller ytterligare efter beskedet.

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

“I am driven by the desire to develop a product that can be sold worldwide”

Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forw...

GSK i stort Kinasamarbete – ska utveckla ett dussin nya läkemedel

Den brittiska läkemedelsjätten GSK har tecknat ett stort samarbetsavtal med kinesiska Hengrui Pharma om utveckling av upp till 12 nya läkemedel.

TCO easy comparison of electric and pneumatic solutions

Find the right technology for your application and compare CO₂ emission and TCO The shown results are not based on a sizing calculation, parameters like service...

Product demo with features, software and best-practices

Get interesting insights about ZEISS O-INSPECT duo in our demo recording.

Conference recordings now available

Don't miss out on insights from leading experts.

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Eli Lilly bygger superdator med techjätte – ska påskynda nya läkemedel

Det amerikanska läkemedelsbolaget Eli Lilly har ingått ett samarbete med techjätten Nvidia för att utveckla en ny AI-superdator som ska påskynda upptäckten och ...

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Pharma Search and Advice AB

Just four weeks to a concept for an emergency ventilator

The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...

Hamlet aviserar vd-byte

Hamlet Biopharma möblerar om i ledningen, och i styrelsen.

Babypuderskandalen når Europa – första stämningen mot J&J i Storbritannien

De enorma skadeståndsprocesserna mot Johnson & Johnson, vars talkpuder påstås ha orsakat cancer, har nu även nått Storbritannien.

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Norway rejects national life science strategy – sees no need

The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.

Cantargia utser Hilde Steineger till ny vd

Det Lundbaserade forskningsbolaget Cantargia har utsett Hilde Steineger till ny vd.

New drug to simplify treatment of hemophilia

A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.